Hand-out
Press Releases
TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients